NASDAQ:APVO Aptevo Therapeutics (APVO) Stock Price, News & Analysis $0.17 -0.01 (-5.55%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aptevo Therapeutics alerts: Email Address About Aptevo Therapeutics Stock (NASDAQ:APVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aptevo Therapeutics alerts:Sign Up Key Stats Today's Range$0.17▼$0.1950-Day Range$0.16▼$0.5852-Week Range$0.14▼$21.56Volume871,876 shsAverage Volume2.61 million shsMarket Capitalization$694,178.10P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewAptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More… The Perfect Storm for an EV Revolt (Ad)With constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves... Not many people realize there’s a "perfect storm" for profits unfolding in the auto industry - today. Or that cars and trucks are actually the world’s biggest business. Click here for details... Aptevo Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 30th PercentileAptevo Therapeutics scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Aptevo Therapeutics.Read more about Aptevo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($4.30) to ($2.28) per share.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aptevo Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.50% of the outstanding shares of Aptevo Therapeutics have been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently decreased by 80.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.50% of the outstanding shares of Aptevo Therapeutics have been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently decreased by 80.24%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News SentimentN/A News SentimentAptevo Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aptevo Therapeutics this week, compared to 0 articles on an average week.Search Interest3 people have searched for APVO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.31% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.06% of the stock of Aptevo Therapeutics is held by institutions.Read more about Aptevo Therapeutics' insider trading history. Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APVO Stock News HeadlinesAptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.comSeptember 20 at 5:47 AM | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.comSeptember 11, 2024 | americanbankingnews.comMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must.September 20, 2024 | Unstoppable Prosperity (Ad)Aptevo Therapeutics: Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia Trial InitiatedAugust 13, 2024 | finanznachrichten.deBiotech Seeing Significant Buying Pressure Before The Opening BellJuly 19, 2024 | theglobeandmail.comAPVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024May 8, 2024 | investorplace.comWhy Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving PremarketMay 2, 2024 | msn.comWhy Aptevo Therapeutics Stock Is CrateringApril 11, 2024 | msn.comSee More Headlines APVO Stock Analysis - Frequently Asked Questions How have APVO shares performed this year? Aptevo Therapeutics' stock was trading at $7.9640 at the start of the year. Since then, APVO shares have decreased by 97.9% and is now trading at $0.1701. View the best growth stocks for 2024 here. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.26. When did Aptevo Therapeutics' stock split? Aptevo Therapeutics shares reverse split on Wednesday, March 6th 2024. The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are Aptevo Therapeutics' major shareholders? Aptevo Therapeutics' top institutional shareholders include Armistice Capital LLC (18.36%) and Concourse Financial Group Securities Inc.. View institutional ownership trends. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK) and AbbVie (ABBV). Company Calendar Last Earnings8/08/2024Today9/20/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APVO CUSIPN/A CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees50Year Founded2016Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-269.26% Return on Assets-119.48% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77 Sales & Book Value Annual Sales$3.11 million Price / Sales0.24 Cash FlowN/A Price / Cash FlowN/A Book Value$28.58 per share Price / Book0.01Miscellaneous Outstanding Shares4,081,000Free Float4,068,000Market Cap$756,209.30 OptionableNot Optionable Beta5.18 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:APVO) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.